Industry
Researchers
Clinicians
Patients & Families
Advocacy Groups
Our Programs
PROGRAMS
PrOSPeCT
Omico’s landmark national precision oncology initiative and the largest cancer genomics initiative in Australia. Through a nationally coordinated platform, it expands access to precision oncology, accelerates research, generates real-world data and helps improve cancer care.
Cancer Screening Program (CaSP)
The screening program associated with PrOSPeCT, providing comprehensive genomic profiling and matching eligible patients with advanced, incurable and poor-prognosis cancers to innovative clinical trials and treatment options.
Molecular Screening and Therapeutics (MoST) study
The pioneering study that laid the foundation for PrOSPeCT, using genomic profiling to understand molecular changes in cancer and match patients with biomarker-led therapies. Recruitment has closed and follow-up research continues.
Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+)
Investigating and evaluating the surveillance practices used for people at high-risk of multi-organ cancer.
Genetic Cancer Risk in the Young (RisC) study – Now closed
Studying genetic variants that contribute to inherited cancer risk in young people. Recruitment has closed and follow-up research continues.
CLINICAL TRIALS
Company Studies (C3)
Companion Studies (C2)
MoST Core Studies (C1)
MoST-LLy
ASPiRATION
Our RWD Offerings
Our Real-World Data Offerings
Based on a unique real-world genomic dataset, built for precision oncology decisions
Our Biospecimens for Research
Access to biospecimens and associated clinical and genomic data to support research and enable discovery in precision oncology
Resources & Events
About Us
About Us
Network & Partners
Our Board
Our Leadership Team
Publications
Annual Reports
Partner Toolkits
News
Contact
Events and Resources
About Us
Our Network & Partners
Our Board
Our Leadership Team
Our Molecular Oncology Board
Publications
Annual Reports
News
Contact Us
Sign up for newsletter
News
Find out more about ASPiRATION
